U.S. Software Stock News

Energy Fuels stock triggered by recent performance Energy Fuels (UUUU) has come onto investors’ radar after a strong share price move, with the stock up about 49% over the past month and 10% over the past week. See our latest analysis for Energy Fuels. That recent momentum sits against a mixed backdrop, with a 30 day share price return of 49.14% and a year to date share price return of 25.36%. The 1 year total shareholder return is very large at over 3x, suggesting sentiment has shifted...

If you are wondering whether Array Technologies stock still offers value at around US$10.00, the key question is how its current price lines up against what the business may be worth. The share price performance has been mixed, with returns of 5.3% over 7 days, 17.4% over 30 days, 3.3% year to date, a 48.1% gain over 1 year, and weaker returns over 3 and 5 years at 57.6% and 79.3% declines. Recent news coverage has focused on Array Technologies as investors reassess solar related names and...

SELLAS Life Sciences Group announced an agreement with IMPACT-AML under which the pan-European network will run a clinical study of SLS009, a selective CDK9 inhibitor, in combination with azacitidine and venetoclax for newly diagnosed high-risk acute myeloid leukemia patients across multiple European sites. By tapping into IMPACT-AML’s EU Mission Cancer-backed STREAM platform, SELLAS can broaden European patient access to SLS009 in a cost-efficient way while its separate REGAL Phase 3 AML...

For investors wondering whether First Busey is offering fair value at its current share price, or whether the recent trading range is creating an opportunity, this article walks through what the numbers are indicating about the stock. The shares last closed at US$23.70, with returns of a 2.4% decline over 7 days and a 5.8% decline over 30 days, while the 1-year and 5-year returns of 9.9% and 23.2% keep longer term holders focused on the broader context. Recent coverage has focused on how...

Concentrix (CNXC) closed out FY 2025 with Q4 revenue of US$2.6b and a basic EPS loss of US$23.83, alongside a net income loss of US$1.5b. On a trailing twelve month basis, revenue stood at US$9.8b with a net loss of US$1.3b and basic EPS of US$20.30. Over recent quarters the company has seen quarterly revenue move from US$2.4b in Q4 2024 to US$2.6b in Q4 2025. However, basic EPS shifted from US$1.73 and net income of US$111.0m in Q4 2024 to a sizable loss in the latest quarter, so the focus...

If you are wondering whether Paylocity Holding's share price around US$144.74 offers good value today, it helps to separate the story from the numbers and look at what the data actually says. Over the last week the stock has recorded a 5.1% decline, while the 1 year return sits at a 24.7% decline. This may prompt questions about whether expectations or perceived risk have shifted. Recent commentary around Paylocity has focused on its position in payroll and human capital management software,...

Wondering whether UP Fintech Holding offers genuine value at its current price, or if the recent excitement has already been priced in? This article breaks down what the numbers are saying about the stock. The share price sits at US$9.52 after a 7 day return of an 8.8% decline, a 30 day return of 3.0%, a year to date return of an 8.8% decline, a 1 year return of 54.5% and a 3 year return of 138.0%, while the 5 year return stands at a 36.2% decline. Recent coverage around UP Fintech Holding...

SS Innovations International recently issued preliminary, unaudited results indicating fourth-quarter 2025 revenue of about US$15.0 million and full-year 2025 revenue of about US$43.0 million, both sharply higher than 2024 levels and driven by increased SSi Mantra surgical robot sales and installations. Alongside this growth, the company expanded its leadership bench by appointing veteran executive Milan Rao as both Chief Financial Officer and Global Chief Operating Officer, underscoring its...

Civitas Resources (CIVI) has drawn attention after a stretch of negative returns. The stock is down about 10% over the past month and 7% over the past 3 months, inviting closer scrutiny from investors. See our latest analysis for Civitas Resources. Those short term moves sit within a tougher stretch for holders, with a year to date share price return of a 5.11% decline and a 1 year total shareholder return of a 47.54% decline, even though the 5 year total shareholder return of a 72.84% gain...

Why Xenia Hotels & Resorts is on investors’ radar Xenia Hotels & Resorts (XHR) has been drawing attention after a period where the stock’s past 3 months return sits around 13%, alongside modest revenue growth and a weaker annual net income result. See our latest analysis for Xenia Hotels & Resorts. At a share price of US$14.75, Xenia Hotels & Resorts has seen a 12.94% 90 day share price return, while its 1 year total shareholder return of 4.92% and 5 year figure close to flat suggest momentum...

Why Tenet Healthcare is on investors’ radar today Tenet Healthcare (THC) has been drawing attention after a period of strong multi year total returns. The stock recently closed at $199.19, and investors are weighing how its current valuation lines up with fundamentals. See our latest analysis for Tenet Healthcare. While the share price has eased in the very short term, with a 7 day share price return of a 4.35% decline to US$199.19, Tenet Healthcare’s 1 year total shareholder return of 56.07%...

If you are wondering whether RenaissanceRe Holdings is still good value at around US$270.10 per share, this breakdown is designed to help you make sense of the current price. The stock’s moves have been relatively muted recently, with a 0.7% decline over the last week, a 0.8% decline over the past month and year to date, and an 8.2% return over one year and 76.5% over five years. Recent attention on RenaissanceRe has centered on how the company is positioned within the insurance and...

Ichor Holdings, Ltd. ( NASDAQ:ICHR ) shares have had a really impressive month, gaining 47% after a shaky period...

Key Insights Given the large stake in the stock by institutions, NewtekOne's stock price might be vulnerable to their...

As the U.S. market navigates through a period of fluctuating indices and economic indicators, small-cap stocks present unique opportunities amid broader market volatility. In this landscape, identifying promising companies requires a keen eye for innovation and resilience, particularly those that can thrive despite challenges such as inflationary pressures and shifting consumer trends.

In the past week, Barclays analyst Brendan Lynch downgraded Lineage, Inc. from an “Overweight” to an “Equal-Weight” stance, reflecting a more cautious view of the company’s near-term prospects. This shift comes as several analysts have recently reduced their enthusiasm for Lineage, signaling a broader reassessment of the company’s outlook and risk profile. Next, we’ll examine how this growing analyst caution, particularly Barclays’ downgrade, may influence Lineage’s investment narrative...

American States Water Company recently reported that its water utility subsidiary, Golden State Water Company, received California Public Utilities Commission approval for full second-year rate increases effective January 1, 2026, increasing adopted 2026 water revenue less water supply cost by about US$32.0 million versus 2025. This decision, enabled by Golden State Water meeting earnings tests across all rate-making areas, reinforces the importance of regulatory outcomes in shaping the...

Alphatec Holdings (ATEC) grabbed attention after its 2026 revenue outlook implied slower growth at the same time the company secured exclusive U.S. rights to Theradaptive’s OsteoAdapt bone graft, sending the stock sharply lower. See our latest analysis for Alphatec Holdings. The guidance update and Theradaptive partnership arrived after a volatile stretch for the shares, with a 24.5% 7 day share price return decline and 17.6% 30 day share price return decline, even as the 1 year total...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Agios Pharmaceuticals recently outlined its 2026 strategic priorities at the 44th Annual J.P. Morgan Healthcare Conference, emphasizing the ongoing U.S. launch of AQVESME (mitapivat) in thalassemia following its December 2025 FDA approval and upcoming regulatory interactions for mitapivat in sickle cell disease. This update underscores how Agios is working to convert its rare disease pipeline into commercial momentum by expanding mitapivat’s reach across multiple hematologic...

Stewards at Sequire Investor Summit: Why This Event Matters Stewards (SWRD) is set to present at the Sequire Investor Summit 2026 in Puerto Rico, where management plans to outline its diversified operating platform and its progress toward a potential uplisting to the Nasdaq Capital Market. See our latest analysis for Stewards. The upcoming Sequire presentation comes after a choppy period for the stock, with a 1-day share price return of 5.26% contrasting with a 7-day decline of 15.25% and a...

UFP Technologies, Inc. ( NASDAQ:UFPT ), might not be a large cap stock, but it received a lot of attention from a...

In early January 2026, NextNRG Inc. reported preliminary unaudited revenue of approximately US$8.01 million for 2025 and highlighted new healthcare microgrid power purchase agreements across assisted living and rehabilitation facilities, showcasing standardized, long-duration energy infrastructure capable of maintaining operations during grid disruptions while supporting regulatory compliance and predictable energy costs. Together, these contracts form a portfolio of long-term, contracted...

KeyBanc recently upgraded Omnicell’s rating from Sector Weight to Overweight and, alongside other brokerage firms, reinforced an overall “Outperform” view on the healthcare technology company focused on autonomous medication management. This wave of more positive analyst opinions arrives just weeks before Omnicell reports its fourth-quarter and full‑year 2025 results, potentially sharpening investor focus on how its automation and cloud-based platforms are progressing. We’ll examine how the...